Bioporto ASTHOXF 66 EPS without NRI is $-0.03 as of Dec. 2025. GuruFocus rates THOXF with a GF Score™ of 66/100 and a GF Value™ of $0.17. The stock has 3 warning signs investors should review. Among 161 Medical Diagnostics & Research companies, Bioporto AS ranks better than 55.28% on this metric.
Bioporto AS's earnings per share without non-recurring items for the
three
months ended in Dec. 2025 was $-0.00.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.03.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 13.50% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 11.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Bioporto AS's EPS without NRI or its related term are showing as below:
THOXF'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.9 Med: 8.2 Max: 28.6
Current: 13.5
During the past 13 years, Bioporto AS's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 28.60% per year. The lowest was -42.90% per year. And the median was 8.20% per year.
THOXF's 3-Year EPS without NRI Growth Rate is ranked better than 55.28% of 161
companies
in the Medical Diagnostics & Research industry
Industry Median: 10.8
vs THOXF: 13.50
Bioporto AS's EPS (Diluted) for the
three
months ended in Dec. 2025 was $-0.00.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.03.
Bioporto AS's EPS (Basic) for the
three
months ended in Dec. 2025 was $-0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.03.
Bioporto AS (OTCPK:THOXF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Bioporto AS EPS without NRI Related Terms
Bioporto AS EPS without NRI Historical Data
* Premium members only.
The historical data trend for Bioporto AS's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THOXF vs TMO, DHR, IDXX: EPS without NRI Comparison
For the Diagnostics & Research subindustry, Bioporto AS's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS PE Ratio without NRI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Bioporto AS's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (THOXF) has a EPS without NRI of $-0.03 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Bioporto AS and its competitors. According to the industry distribution chart, Bioporto AS ranks #72 out of 161 companies in the Medical Diagnostics & Research industry, placing it in the top 44.7%.
Is Bioporto AS's EPS without NRI too high?
Bioporto AS's current EPS without NRI is $-0.03. Based on the distribution chart, Bioporto AS ranks #72 out of 161 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Bioporto AS has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's EPS without NRI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #72 out of 161 companies for EPS without NRI. This puts Bioporto AS in the upper half of its industry. The industry median EPS without NRI is 10.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.80, based on 161 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current EPS without NRI is $-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current EPS without NRI of $-0.03. The stock's GF Value™ is $0.17, compared to a current price of $0.15 — trading 12.4% below its estimated fair value. The current EPS without NRI is $-0.03. Bioporto AS's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Bioporto AS (THOXF), the current EPS without NRI is $-0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 12.4% below its estimated GF Value™ of $0.17.
Key valuation signals for THOXF:
EPS without NRI: $-0.03
GF Value™: $0.17 vs. price of $0.15 (12.4% below fair value)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
66GF Score
Get the complete analysis for THOXF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
